Product Name
KCNQ3, siRNA
Full Product Name
KCNQ3 siRNA (Human)
Product Synonym Names
Potassium voltage-gated channel subfamily KQT member 3; KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3
Product Gene Name
KCNQ3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for O43525
Specificity
KCNQ3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human KCNQ3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of KCNQ3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
KCNQ3 sirna
siRNA to inhibit KCNQ3 expression using RNA interference
Applications Tested/Suitable for KCNQ3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for KCNQ3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001191753.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001204824.1
[Other Products]
UniProt Primary Accession #
O43525
[Other Products]
UniProt Secondary Accession #
A2VCT8; B4DJY4; E7EQ89[Other Products]
UniProt Related Accession #
O43525[Other Products]
Molecular Weight
93,599 Da
NCBI Official Full Name
potassium voltage-gated channel subfamily KQT member 3 isoform 2
NCBI Official Synonym Full Names
potassium channel, voltage gated KQT-like subfamily Q, member 3
NCBI Official Symbol
KCNQ3??[Similar Products]
NCBI Official Synonym Symbols
EBN2; BFNC2; KV7.3
??[Similar Products]
NCBI Protein Information
potassium voltage-gated channel subfamily KQT member 3
UniProt Protein Name
Potassium voltage-gated channel subfamily KQT member 3
UniProt Synonym Protein Names
KQT-like 3; Potassium channel subunit alpha KvLQT3; Voltage-gated potassium channel subunit Kv7.3
Protein Family
Potassium voltage-gated channel subfamily
UniProt Gene Name
KCNQ3??[Similar Products]
UniProt Entry Name
KCNQ3_HUMAN
NCBI Summary for KCNQ3
This gene encodes a protein that functions in the regulation of neuronal excitability. The encoded protein forms an M-channel by associating with the products of the related KCNQ2 or KCNQ5 genes, which both encode integral membrane proteins. M-channel currents are inhibited by M1 muscarinic acetylcholine receptors and are activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2). Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014]
UniProt Comments for KCNQ3
Kv7.3: Probably important in the regulation of neuronal excitability. Associates with KCNQ2 or KCNQ5 to form a potassium channel with essentially identical properties to the channel underlying the native M-current, a slowly activating and deactivating potassium conductance which plays a critical role in determining the subthreshold electrical excitability of neurons as well as the responsiveness to synaptic inputs. Defects in KCNQ3 are the cause of benign familial neonatal seizures type 2 (BFNS2). A disorder characterized by clusters of seizures occurring in the first days of life. Most patients have spontaneous remission by 12 months of age and show normal psychomotor development. The disorder is distinguished from benign familial infantile seizures by an earlier age at onset. Belongs to the potassium channel family. KQT (TC 1.A.1.15) subfamily. Kv7.3/KCNQ3 sub-subfamily.
Protein type: Membrane protein, multi-pass; Membrane protein, integral; Channel, potassium
Chromosomal Location of Human Ortholog: 8q24
Cellular Component: voltage-gated potassium channel complex; integral to membrane; plasma membrane
Molecular Function: voltage-gated potassium channel activity; potassium channel activity; delayed rectifier potassium channel activity
Biological Process: axon guidance; synaptic transmission; membrane hyperpolarization; potassium ion transport
Disease: Seizures, Benign Familial Neonatal, 2
Research Articles on KCNQ3
1. mutations in KCNQ3, similarly to KCNQ2, can be found in patients with more severe phenotypes including intellectual disability
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
